For more than two decades, the Medicare Inpatient-Only (IPO) List has served as a clear guide for healthcare organizations and physicians. Procedures on the list could only be reimbursed by Medicare when performed in an inpatient setting, creating a predictable pathway for admission status, documentation, utilization review, and reimbursement.
That framework is now changing. The Centers for Medicare Medicaid Services (CMS) has begun a three-year phase-out of the IPO List, starting in 2026 with the removal of hundreds of procedures and culminating in its complete elimination by 2029. While the change is intended to give physicians greater flexibility in determining the most appropriate site of care, it also shifts more responsibility to hospitals and health systems to justify why a patient should receive inpatient care.
As the IPO List disappears, the risk to reimbursement in instances where healthcare organizations continue to rely on workflows built around rules that no longer exist is significant. IPO readiness depends on having the right processes in place to ensure admission status, authorization, documentation, and clinical review decisions are accurate and defensible. Procedures that once followed a relatively straightforward inpatient pathway now (or soon will) require patient-specific clinical justification, stronger medical necessity documentation, and closer coordination across authorization, utilization review, physician advisory, clinical documentation, coding, and denials management teams.
For revenue cycle leaders, utilization review (UR) teams, physician advisors, Clinical Documentation Integrity (CDI) specialists, patient access leaders, and denials professionals, the challenge is practical: prevent revenue loss. Successfully navigating the IPO phase-out requires identifying and addressing six potential points of failure that can undermine appropriate site-of-care decisions and expose the healthcare organization to avoidable financial risk.
Gap 1: No visibility into high-risk procedures.
The first IPO readiness gap is the lack of procedure-level visibility. Many healthcare organizations begin with broad education, but a stronger starting point is a focused risk inventory.
Not every procedure removed from the IPO List creates the same level of risk. Teams should identify which procedures require the closest review based on volume, payer mix, historical inpatient utilization, reimbursement variance, denial history, and physician practice patterns.
A practical watchlist includes:
- Procedure volume
- Payer mix
- Historical inpatient utilization
- Reimbursement variance
- Existing denial patterns
- Physician practice trends
This focus allows teams to prioritize resources where operational and financial risk are highest and not miss the cases most likely to cause avoidable revenue leakage.
Gap 2: Authorization decisions are accepted without review.
Authorization mismatches (for example, outpatient authorization on file for a procedure planned as inpatient) are already too common even before taking into account the IPO phase-out. Now, with a significant number of procedures removed from the list in 2026, these mismatch occurrences are rising: a payer may approve outpatient status for a procedure that historically followed an inpatient pathway. The authorization may then be accepted as routine, even when the patient's risk profile or expected recovery supports closer review.
Healthcare organizations should establish pre-service review processes for cases involving:
- High-risk procedures
- Significant comorbidities
- Complex recovery expectations
- Medical necessity concerns
- Authorization and clinical status mismatches
The goal is to identify preventable risk while the healthcare organization still has time to clarify status, gather clinical support, and escalate the case when needed, rather than handle it after reimbursement is challenged or denied by the payer.
Gap 3: Physician advisors become involved too late.
Physician advisor review can have greater value when it occurs before a denial. Many hospitals and health systems rely primarily on physician advisors for acute level of care decisions (observation vs. inpatient) and clinically based appeals, but IPO-related risk often requires prospective input.
Healthcare organizations should define clear escalation criteria for physician advisor review, including:
- High-risk procedures
- Significant reimbursement variance
- Complex clinical presentations
- Unclear medical necessity
- Potential status changes
- Delayed recovery or post-procedure complications
Earlier physician advisor involvement can strengthen status decisions, improve documentation, and support payer conversations to prevent before claim denials.
Gap 4: Documentation describes the procedure but not the patient.
IPO readiness depends on documentation that explains why the patient required inpatient level of care. As IPO protections disappear, the procedure code itself no longer makes the inpatient case. The record must connect the patient's specific condition(s) and risk factors, the anticipated intensity of service and monitoring needs, as well as the expected clinical course and site-of-care decision.
Documentation should support:
- Medical necessity
- Patient-specific risk factors
- Expected intensity of service
- Monitoring requirements
- Site-of-care rationale
- Changes in clinical condition
Status determination checklists, as part of prior authorization request workflows, can improve consistency, but they cannot replace a defensible, patient-specific clinical narrative in the record. A checked box can help teams remember what to evaluate, but it will never be a substitute for the clinical documentation that clearly explains why inpatient care was necessary as the only appropriate admission status for that particular patient.
Gap 5: Concurrent review stops too soon.
Site-of-care review should continue after the initial status decision. Patients do not always recover as expected. Complications occur. Recovery timelines change. Additional monitoring may become necessary. Clinical conditions evolve during the encounter.
Utilization review and physician advisor teams should reassess status when the clinical course changes. That includes delayed discharge, unexpected post-procedure complications, additional services, changing monitoring needs, and payer-specific requirements for status updates.
Waiting until discharge or denial review reduces the healthcare organization's ability to address reimbursement risk while the clinical story is still being documented. A robust, real-time review workflow for outpatients unable to be discharged as expected same-day, as well as inpatients unable to receive their planned procedures, can protect revenue by getting updated clinical details and authorization requests to the payer within 24 hours of the change or update in the provider’s plan.
Gap 6: Denials data never makes it back upstream.
Denials should be treated as operational intelligence. If denial trends remain downstream, teams repeat the same preventable errors across scheduling, authorization, utilization review, documentation, and provider workflows.
Revenue cycle leaders should analyze:
- Denial reasons
- Appeal outcomes
- Authorization trends
- Documentation deficiencies
- Payer-specific patterns
- Areas of recurring revenue risk
- Underpayment trends that may not appear in standard denial workflows
It is critical to close the loop. Findings should be shared with scheduling teams, authorization specialists, utilization review staff, physician advisors, CDI professionals, coders, denials teams, and providers in a format that enables them to act.
IPO readiness workflow map
| Workflow gap | Primary owners | Prevention action |
|---|---|---|
| Limited procedure visibility | Revenue cycle, finance, service line leaders | Build a procedure watchlist by volume, payer, status pattern, and reimbursement variance. |
| Authorization mismatch | Patient access, prior authorization, UR | Flag outpatient approvals for high-risk cases before the encounter. |
| Late physician advisor review | UR, physician advisory, case management | Create escalation triggers for prospective and concurrent review. |
| Weak patient-specific documentation | Providers, CDI, UR | Document medical necessity, risk factors, intensity of service, and site-of-care rationale. |
| Insufficient concurrent review | UR, physician advisors | Reassess status when recovery, monitoring, or complications change. |
| Downstream-only denial review | Denials, analytics, RCM operations | Translate denial patterns into upstream workflow changes and education. |
What should a mature IPO readiness process include?
A mature IPO readiness strategy creates alignment across the entire patient journey.
Revenue cycle leaders should be able to answer six questions:
- Which procedures create the greatest site-of-care and reimbursement risk for our organization?
- Which cases require additional pre-service review?
- When should physician advisors be engaged?
- What documentation supports a defensible admission decision?
- How are status changes managed during the encounter?
- How are denials and underpayments driving operational improvements?
Healthcare organizations that answer these questions proactively will be better positioned to prevent revenue leakage as payer scrutiny increases.
Strengthening your IPO readiness strategy
The IPO phase-out changes how hospitals and health systems determine admission status, document medical necessity, and protect reimbursement. Strong IPO readiness means shifting attention upstream: before authorization is finalized, before the patient arrives, before the claim is submitted, and before a denial occurs.
A flexible revenue cycle management (RCM) services partner can help health systems extend capacity across clinical authorization, utilization review, physician advisory support, clinical denials, and analytics. Contact AGS Health to learn more about how we can support your IPO readiness strategy to meet new demands across utilization review, physician advisory, clinical documentation integrity, authorization management, and denial prevention.
